Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Alembic Pharmaceuticals Ltd 路 Press Release 路 18 Oct 2026, 12:22 am
Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Alembic Pharmaceuticals received USFDA final approval on 17th Oct'26 for its ANDA Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, therapeutically equivalent to Sandoz Inc.'s Ciprodex. The product is indicated for acute otitis media and acute otitis externa. Per IQVIA data, the product's estimated market size was US$110mn for the 12 months ending Jun'26. With this nod, Alembic holds a cumulative total of 246 USFDA ANDA approvals, comprising 226 final and 20 tentative approvals.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
